Goldline Pharmaceutical IPO Day 3 Subscription Status Stood At 840X

By Kotak News Desk
|
14 May 2026 at 5:54 PM IST
|
Market News
|
4m

Stay updated with the latest stock market developments and trends.

You can set Kotak Neo as a preferred source to receive regular market updates.

Summary

The subscription status of Goldline Pharmaceutical IPO stood at 840.74 times on day 3, with strong participation from NIIs and retail investors.

Goldline Pharmaceutical’s initial public offering (IPO) was subscribed 840.74 times on day 3 (14 May 2026). Through its initial public offering, Goldline Pharmaceutical seeks to raise ₹11.61 crore. Today was the last day of bidding for this IPO, which opened for subscription on 12 May.

Just like the first two days of bidding, the IPO saw strong participation from non-institutional investors (NIIs) and retail investors today. However, the response from qualified institutional bidders (QIBs) was a little muted.

Goldline Pharmaceutical IPO Day 3 Subscription Status

The table highlights the subscription status of various categories of investors for the Goldline Pharmaceutical IPO on day 3:


Anchor	1	7,32,000	7,32,000	3.15
Market Maker	1	1,38,000	1,38,000	0.59
QIB (Ex-Anchor)	180.22	5,40,000	9,73,17,000	418.46
NII	1662.04	3,90,000	64,81,95,000	2787.24
Individual Investors	881.15	9,00,000	79,30,38,000	3410.06
Total	840.74	18,30,000	1,53,85,50,000	6615.77

Goldline Pharmaceutical IPO Day-Wise Subscription Status

The table below highlights the day-wise subscription status of the Goldline Pharmaceutical IPO:


May 12 (Day 1)	1.31	24.46	22.52	28.25	34.07	22.35
May 13 (Day 2)	1.31	146.12	159.99	119.02	139.51	100.14
May 14 (Day 3)	180.22	1662.04	2010.60	980.75	881.15	840.74

Goldline Pharmaceutical IPO And Its Timeline

The table highlights the key details of this IPO:


IPO Close Date	14 May
Allotment Of Bids	15 May
Lot Size	3000
Price Range	₹41-₹43
Initiation Of Refund	18 May
Listing Date	19 May

Goldline Pharmaceutical is engaged in the marketing of pharma products under the ‘Goldline’ brand name. The company’s products are organised into five segments, namely:

Goldline Pharma
Goldline Cardinal
Goldline Aayushman
Goldline InLife
Goldline Wellness

Also Read - Post-Market, 14 May 2026: Sensex Zooms Past 75,350; Nifty Gains 1.18%

The company plans to use the IPO proceeds for repaying certain outstanding borrowings and general corporate purposes.

Sources:

Chittorgarh

RHP

This article is for informational purposes only and does not constitute financial advice. It is not produced by the desk of the Kotak Securities Research Team, nor is it a report published by the Kotak Securities Research Team. The information presented is compiled from several secondary sources available on the internet and may change over time. Investors should conduct their own research and consult with financial professionals before making any investment decisions. Read the full disclaimer here.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Brokerage will not exceed SEBI prescribed limit. The securities are quoted as an example and not as a recommendation. SEBI Registration No-INZ000200137 Member Id NSE-08081; BSE-673; MSE-1024, MCX-56285, NCDEX-1262.

About the Author